论文部分内容阅读
卵巢癌是致死率最高的妇科恶性肿瘤,其发病机制的探讨是肿瘤研究领域的难点,近年研究发现卵巢癌的发生与表观遗传学改变密切相关,针对影响表观遗传的重要分子靶标组蛋白去乙酰化酶的研究成为新热点。组蛋白去乙酰化酶抑制剂(HDAC Is)可以明显地抑制卵巢癌细胞生长,诱导细胞周期阻滞、分化和凋亡,抑制卵巢癌相关致癌基因的表达,具有抗肿瘤活性且无明显不良反应,提示HDACIs为卵巢癌的治疗提供了一种新策略。
Ovarian cancer is the highest fatal rate of gynecological malignancies, the pathogenesis of the study is difficult in the field of cancer research, recent studies found that the occurrence of ovarian cancer and epigenetic changes are closely related to the impact of epigenetic important molecular target histone The study of deacetylase has become a new hot spot. Histone deacetylase inhibitor (HDAC Is) can significantly inhibit ovarian cancer cell growth, induce cell cycle arrest, differentiation and apoptosis, inhibit the expression of ovarian cancer-associated oncogenes, have anti-tumor activity and no obvious adverse reactions , Suggesting that HDACIs provide a new strategy for the treatment of ovarian cancer.